Search

Author/Creator Lukic, Tatjana

2. Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift). Issue 2 (8th June 2021)

Authors:
Cohen, Stanley B; Pope, Janet; Haraoui, Boulos; Mysler, Eduardo; Diehl, Annette; Lukic, Tatjana; Liu, Shixue; Stockert, Lori; Germino, Rebecca; Menon, Sujatha; Shi, Harry; Keystone, Edward C
Journal:
RMD open
Issue:
Volume 7:Issue 2(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study. Issue 3 (3rd March 2023)

Authors:
Reyes, Juan M.; Gutierrez‐Ardila, Magda V.; Madariaga, Hugo; Otero, William; Guzman, Renato; Izquierdo, Jorge; Del Castillo, David J.; Abello, Mauricio; Velez, Patricia; Ponce de Leon, Dario; Lukic, Tatjana; Amador, Luisa F.; Castaño, Natalia
Journal:
Health science reports
Issue:
Volume 6:Issue 3(2023)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. LB0004 METHOTREXATE WITHDRAWAL IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVE LOW DISEASE ACTIVITY WITH TOFACITINIB MODIFIED-RELEASE 11 MG ONCE DAILY + METHOTREXATE: A RANDOMISED NON-INFERIORITY PHASE 3B/4 STUDY. (June 2019)

Authors:
B. Cohen, Stanley; Pope, Janet; Haraoui, Boulos; Irazoque-Palazuelos, Fedra; Korkosz, Mariusz; Diehl, Annette; Luis Rivas, Jose; Lukic, Tatjana; Liu, Shixue; Stockert, Lori; Iikuni, Noriko; Keystone, Edward
Journal:
Annals of the rheumatic diseases
Issue:
Volume 78(2019)Supplement 2
Page Start:
260
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. (September 2019)

Authors:
Cohen, Stanley B; Pope, Janet; Haraoui, Boulos; Irazoque-Palazuelos, Fedra; Korkosz, Mariusz; Diehl, Annette; Rivas, Jose L; Lukic, Tatjana; Liu, Shixue; Stockert, Lori; Iikuni, Noriko; Keystone, Edward C
Journal:
Lancet
Issue:
Volume 1:Number 1(2019)
Page Start:
e23
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study. (17th August 2018)

Authors:
Tanaka, Yoshiya; Sugiyama, Naonobu; Toyoizumi, Shigeyuki; Lukic, Tatjana; Lamba, Manisha; Zhang, Richard; Chen, Connie; Stock, Thomas; Valdez, Hernan; Mojcik, Christopher; Fan, Haiyun; Deng, Chenhui; Yuasa, Hirotoshi
Journal:
Rheumatology
Issue:
Volume 58:Number 1(2019)
Page Start:
70
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗